argenx SE
corporate_fare Company Profile
argenx SE (NASDAQ:ARGX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for ARGX at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- ARGENX Reports Record 2025 Financials with $4.2B Sales, $1.3B Profit; Advances Key VYVGART Regulatory Milestones
- Argenx to Present Broad Positive Clinical Data at AAN, Including New Pipeline Proof-of-Concept
- ARGENX Achieves First Operating Profitability with $1.1B in 2025, Reports $4.2B Sales & Positive Phase 3 VYVGART Data in Ocular MG
- ARGENX VYVGART Phase 3 Trial for Ocular MG Meets Primary Endpoint, Paving Way for Label Expansion
- ARGENX Receives FDA Priority Review for VYVGART sBLA in Seronegative gMG, Targeting Expanded Patient Population
Financial Snapshot
Insider Transactions
ARGX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.